Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Doris K. Hansen, Surbhi Sidana, Lauren Peres, Leyla Shune, Douglas W. Sborov, Hamza Hashmi, Mehmet H. Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher J. Ferreri, Aimaz Afrough, Ankit J. Kansagra, Peter M. Voorhees, Melissa Alsina, Joseph McGuirk, Frederick L. Locke, Krina K. Patel
Institutions: Moffitt Cancer Center, Stanford University, The University of Kansas Cancer Center, University of Utah, Huntsman Cancer Institute, Medical University of South Carolina, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Levine Cancer Institute, VCU Massey Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281664214